1. Home
  2. LODE vs CHRS Comparison

LODE vs CHRS Comparison

Compare LODE & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Comstock Inc.

LODE

Comstock Inc.

HOLD

Current Price

$2.56

Market Cap

211.8M

Sector

Industrials

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.13

Market Cap

177.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LODE
CHRS
Founded
1999
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
211.8M
177.7M
IPO Year
2004
2014

Fundamental Metrics

Financial Performance
Metric
LODE
CHRS
Price
$2.56
$1.13
Analyst Decision
Hold
Strong Buy
Analyst Count
2
4
Target Price
$4.00
★ $5.51
AVG Volume (30 Days)
★ 1.1M
1.1M
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
63.55
★ 472.00
EPS
N/A
★ N/A
Revenue
★ $1,553,796.00
N/A
Revenue This Year
$1,582.85
$73.08
Revenue Next Year
$246.20
$30.94
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$2.35
$1.09
52 Week High
$4.98
$2.62

Technical Indicators

Market Signals
Indicator
LODE
CHRS
Relative Strength Index (RSI) 32.76 37.82
Support Level $2.39 N/A
Resistance Level $3.61 $1.53
Average True Range (ATR) 0.18 0.09
MACD -0.01 -0.02
Stochastic Oscillator 17.93 0.00

Price Performance

Historical Comparison
LODE
CHRS

About LODE Comstock Inc.

Comstock Inc commercializes technologies that convert underutilized waste and natural resources into clean energy and supporting products, including electrification, metals, and minerals from end-of-life solar panels. Its subsidiary focuses on producing renewable fuels from waste, energy crops, and woody biomass, supported by facilities in Wisconsin, pilot farms, a biorefinery site in Tulsa, and solar panel recycling operations in Nevada. The Company operates through two high-growth segments and a corporate segment, with its activities grouped into Metals, which generates the majority of revenue, Fuels, Mining, Strategic Investments, and Corporate Services.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: